Table 3.
Summary of Continuing Chemotherapy Regimens and other treatments.
| Immediate Additional Chemotherapy | |
|---|---|
| Yes | 16 |
| No (Upon further T CA 19-9) | 9 |
| Commonly used Upfront agents | |
| Capecitabine/5-FU | 10 |
| Oxaliplatin-based | 9 |
| Irinotecan-based | 1 |
| Nab-paclitaxel | 1 |
| Docetaxel-based | 3 |
| Cisplatin-based | 1 |
| Number of Regimens | |
| 1 | 8 |
| >1 | 17 |
| Oxaliplatin | 2 |
| Irinotecan | 1 |
| Nab-paclitaxel | 1 |
| 5-FU/Capecitabine | 3 |
| Erlotinib | 1 |
| Mitomycin-C | 4 |
| Clinical Trial | 7 |
| Tamoxifen | 1 |
| Onivyde | 3 |
| Radiotherapy | |
| During Adjuvant | 2 |
| Post-Adjuvant (during Additional Chemo) | 4 |
| Surgery | |
| Lungs | 2 |
| Liver | 1 |
| HIPEC | 1 |
| Liver-directed Therapy | |
| Y90 | 3 |
| RFA | 1 |